BP-897 Bioprojet
Preti A.
Genneruxi Medical Center,
via Costantinopoli 42, I-09129,
Cagliari, Italy.
[email protected]
Curr Opin Investig Drugs 2000 Sep;1(1):110-5


BP-897 is a dopamine D3 receptor agonist which is under development by Bioprojet for the potential treatment of drug craving and vulnerability to relapse that are elicited by drug-associated environmental stimuli; it is undergoing phase I trials [318397,334036,340721]. Preclinical investigations were carried out by Cambridge University and INSERM [295680]. BP-897 functions as a partial agonist in vitro and as either an agonist or an antagonist in vivo. It inhibits cocaine-seeking behavior that depends upon the presentation of drug-associated cues, without having any intrinsic, primary rewarding effects [334036]. In preclinical studies, BP-897 administration before testing reduced cocaine-seeking behavior in rats in a dose-dependent manner [304557,307758,334036]. In D3 receptor knockout mice, BP-897 has no effect [345710]. It does not reduce self-administration of cocaine in monkeys [318397].

BP 897
Oral cocaine
Cocaine hotspots
Dopaminergic agents
The coke-craving brain
Monoamines, cocaine and rats
Dopamine D3, sensitization and psychosis
BP 897, dopamine D3 receptors and cocaine

01 02 03 04 05 06 07 08 09 10 11 12
13 14 15 16 17 18 19 20 21 22 23 24

BLTC Research
Wirehead Hedonism
The Hedonistic Imperative
When Is It Best to Take Crack Cocaine?

swan image
The Good Drug Guide
The Responsible Parent's Guide To
Healthy Mood Boosters For All The Family